Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17263930 | 0.82 | TSHR (0.64) | ALDH1A1TSHRTDP1CYP3A4HSD17B10 | |
| SCHEMBL4685683 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TSHRTDP1CYP3A4KDM4E | |
| SCHEMBL19251836 | 0.79 | TSHR (0.50) | ALDH1A1TSHRTDP1CYP3A4PARP1 | |
| SCHEMBL6537796 | 0.75 | CCR8 (0.53) | ALDH1A1TSHRTDP1CYP3A4KDM4E | |
| SCHEMBL15830721 | 0.75 | TSHR (0.46) | ALDH1A1TSHRTDP1CYP3A4PARP1 | |
| SCHEMBL2264374 | 0.74 | ALDH1A1 (0.49) | ALDH1A1TSHRTDP1CYP3A4PARP1 | |
| SCHEMBL2263016 | 0.72 | PARP1 (0.52) | ALDH1A1TDP1CYP3A4PARP1KDM4E | |
| SCHEMBL2262480 | 0.72 | PARP1 (0.43) | ALDH1A1TDP1CYP3A4PARP1KDM4E | |
| SCHEMBL2263585 | 0.72 | PARP1 (0.52) | ALDH1A1TDP1CYP3A4PARP1KDM4E | |
| SCHEMBL3537387 | 0.71 | ALDH1A1 (0.49) | ALDH1A1TSHRTDP1CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363424-B1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250051351-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2025-02-13 | — | — | US | disclosed |
| US-11999749-B2 | Synthesis of a bis-mesylate salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide and intermediates thereto | GENENTECH, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4363424-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | Genentech, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117580840-A | Synthesis of bis-mesylate salt of 4-amino-N- (1- ((3-chloro-2-fluorophenyl) amino) -6-methylisoquinolin-5-yl) thieno [3,2-D ] pyrimidine-7-carboxamide and intermediates thereof | 基因泰克公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230028651-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2023278981-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20140005198-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8557830-B2 | RAF kinase modulators and methods of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557830-B2 | RAF kinase modulators and methods of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-7989461-B2 | Substituted quinazolinamine compounds for the treatment of cancer | AMGEN INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2170887-A2 | HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS | Amgen Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008153947-A2 | HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS | AMGEN INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1976836-A2 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | Amgen Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008112205-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007076092-A2 | NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | ALDH1A1 2020/4885TSHR 1037/4885TDP1 2349/4885 |
| US-20250051351-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | BRAF, RAF1, KRAS | ALDH1A1 1758/4885TSHR 1196/4885TDP1 1379/4885 |
| US-20230028651-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | BRAF, RAF1, KRAS | ALDH1A1 1412/4885TSHR 1190/4885TDP1 1464/4885 |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | ALDH1A1 1799/4885TSHR 1149/4885TDP1 2380/4885 |
| US-11999749-B2 | Synthesis of a bis-mesylate salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide and intermediates thereto | BRAF, RAF1, KRAS | ALDH1A1 1775/4885TSHR 1201/4885TDP1 1307/4885 |
| US-20140005198-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | ALDH1A1 1825/4885TSHR 1077/4885TDP1 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.